Next-Gen Medical AI Tools Gain Traction Across Hospitals and Clinics
Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence is rapidly evolving from a theoretical concept in healthcare to a critical part of clinical operations. As concerns over preventable medical errors persist, AI is being deployed to help reduce risks in areas like medication dosing, diagnosis, and treatment selection. With adoption accelerating across hospitals, research labs, and health tech platforms, several companies are beginning to implement AI tools in real-world care environments. Recent developments include initiatives from Avant Technologies, Inc. (OTCQB: AVAI), Alibaba Group Holding Ltd. (NYSE: BABA), Microsoft Corporation (NASDAQ: MSFT), SoundHound AI, Inc. (NASDAQ: SOUN), and NVIDIA Corporation (NASDAQ: NVDA).
Cathie Wood of Ark Invest recently pointed to a study from Mass General Brigham, where AI models successfully predicted cancer survival outcomes using facial photographs—highlighting what she sees as healthcare’s potential to become AI’s most transformative application. Supporting that outlook, Statista projects the global AI healthcare market to surge from approximately $11 billion to $188 billion by 2030, representing a 37% compound annual growth rate.
Avant Technologies, Inc. (OTCQB: AVAI), in collaboration with Ainnova Tech, is quietly building a foothold in the emerging field of predictive diagnostics. Its Vision AI platform is designed to identify disease markers at the earliest possible stage—sometimes before outward symptoms emerge—by leveraging artificial intelligence in combination with clinical data. In its latest move, Avant disclosed plans to integrate a patented technology that targets early-stage dementia detection, signaling an intentional broadening of its preventive care focus.
The proposed tool uses proprietary algorithms alongside hardware and a five-minute blood test to flag dementia-associated risk factors well in advance of standard clinical methods. Avant is weighing both licensing and acquisition options for the technology, with global rights under consideration. Either route would strengthen the company’s position in the neurodegenerative care space and complement its broader push into chronic illness screening. By expanding its platform’s range without departing from its central thesis—early, accessible intervention—Avant is quietly aiming to reshape how and when critical conditions are first detected.
“This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years,” said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC). “Adding the early detection of dementia that this patented technology presents us would go a long way to making us a leader in the industry of early disease detection.”
Vision AI is designed as a non-invasive platform that brings together retinal imaging, blood pressure readings, and routine lab data to generate personalized health assessments. Its core function is to estimate risk for common but often underdiagnosed chronic conditions—helping clinicians make earlier, more informed decisions with minimal burden on the patient.
By analyzing just two retinal images and a short set of vital signs, the system runs four proprietary algorithms trained on more than 2.3 million clinical records. These algorithms evaluate indicators linked to cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The technology’s lightweight, modular design is intended to keep costs low while enabling use across a wide range of clinical settings—including those with limited access to specialist care.
“Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,” said Vargas in a previous statement. “We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”
Alongside its dementia screening initiative, Avant is progressing toward a full acquisition of Ainnova Tech, its current development partner. The two firms are already operating under a shared entity—Ai-nova Acquisition Corp. (AAC)—and a completed merger would align leadership, simplify corporate structure, and create a more efficient framework for navigating regulatory milestones. A key FDA pre-submission meeting is scheduled for July, making the timing of this integration especially relevant. Internally, management views the consolidation as a strategic lever to accelerate U.S. market access while continuing to support ongoing deployments in international pilot programs.
“This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vargas. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product.”
While many AI-driven diagnostic platforms remain confined to controlled pilots or lab settings, Avant’s Vision AI is already operating in live clinical environments across Latin America. Active deployments in Chile, Mexico, and Brazil are generating real-world data on safety, performance, and clinical usability—insights that are feeding directly into iterative improvements across the platform.
Longer term, the company aims to unify a growing range of diagnostic tools under a single, streamlined system capable of delivering early-stage health insights from basic, non-invasive inputs. Backed by global platform rights through AAC, and supported by detection sensitivity levels reported above 90% in research cited by the NIH, Vision AI is quietly shaping into a scalable solution with potential utility across both developed and underserved healthcare systems.
With dementia screening now entering the pipeline and additional modules under evaluation, Avant appears to be transitioning from early validation to broader execution—laying the groundwork for international expansion and a future U.S. launch.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Alibaba Group Holding Ltd. (NYSE: BABA) has unveiled a healthcare-focused AI model that achieved “Deputy Chief Physician”–level performance on China’s medical exams, signaling significant progress in clinical AI capability.
"The healthcare model is powered by Alibaba’s Qwen 2.5-32B foundation model, supported by extensive, high-quality data and advanced multi-stage training," said Alibaba Group Holdings in its official statement. "It has been refined for better accuracy in conjunction with hospitals and medical institutions, which are adopting the model in their own applications."
Built on the Qwen 2.5-32B model and trained using high-quality data, the tool was benchmarked against models like OpenAI’s GPT-4o and DeepSeek—and outperformed both in test accuracy. Now integrated into Alibaba’s Quark app, the system is being deployed by medical institutions for diagnostic and support tasks. With over 200 million users already on Quark, Alibaba is positioning its AI tools for both consumer and clinical healthcare use cases.
Microsoft Corporation’s (NASDAQ: MSFT) DAX Copilot is gaining momentum as one of the leading ambient-listening AI tools used to document doctor-patient interactions in real time.
"This is a co-pilot, not a pilot or an autopilot, and the physician is always in command of the situation," said Joe Petro, Vice President of Health and Life Sciences for Microsoft. "The goal is to help doctors, not replace their judgment."
Major U.S. healthcare systems—including Stanford, Mass General Brigham, and University of Michigan Health—have begun deploying the technology at scale to reduce administrative burdens and improve physician focus during patient care. Microsoft is also developing diagnostic support features and working with partners like Canary Speech and Press Ganey to expand the system’s capabilities and empathy feedback.
SoundHound AI, Inc. (NASDAQ: SOUN) has launched a healthcare-focused AI agent called “Alli” in partnership with Allina Health to enhance patient engagement and streamline call center operations.
"Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation."
Integrated directly with electronic medical records, the system handles appointment scheduling, authentication, and common inquiries—reducing average call times and improving access without added staffing. The AI agent has already improved call performance metrics while freeing up representatives to focus on more complex patient needs.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) has received FDA approval to expand the use of its Optison ultrasound enhancing agent to pediatric patients, allowing for clearer imaging in echocardiograms when standard ultrasound falls short.
"This regulatory approval is a significant milestone that affirms the safety and efficacy of Optison in pediatric patients of all ages," said Jit Saini, MD, Chief Medical Officer of the Pharmaceutical Diagnostics segment of GE HealthCare. "By facilitating more accurate measurement of left ventricular function, Optison enhances diagnostic capabilities, ultimately improving patient outcomes and providing greater value to healthcare providers and their patients."
Optison is the only PEG-free agent of its kind in the U.S., making it suitable for patients with PEG sensitivities. The approval follows a successful Phase IV study showing improved diagnostic clarity and reduced suboptimal imaging in children.
CONTACT:
Baystreet.ca
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
